Drug Profile

ROSE 010

Alternative Names: GTP-010; LY-307161 SR; ROSE-010

Latest Information Update: 14 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Eli Lilly and Company
Developer Eli Lilly and Company; Rose Pharma
Class Antihyperglycaemics; Glucagon-like peptides; Peptides
Mechanism of Action Glucagon-like peptide 1 stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Irritable bowel syndrome; Obesity
Discontinued Dyspepsia; Type 2 diabetes mellitus

Most Recent Events

09 Sep 2026 Rose Pharma in-licenses Technosphere dry-powder inhalation technology from MannKind Corporation
09 Sep 2026 Preclinical trials in Obesity in Denmark (Inhalation)
09 Sep 2026 Efficacy and adverse events data from a phase II trial in Obesity released by Rose Pharma

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com